- Home
- FGBI vs OBIO Comparison
FGBI vs OBIO Comparison
Compare FGBI & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGBI
- OBIO
- Stock Information
- Founded
- FGBI 1934
- OBIO 2017
- Country
- FGBI United States
- OBIO United States
- Employees
- FGBI N/A
- OBIO N/A
- Industry
- FGBI Savings Institutions
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- FGBI Finance
- OBIO Health Care
- Exchange
- FGBI Nasdaq
- OBIO Nasdaq
- Market Cap
- FGBI 121.9M
- OBIO 124.9M
- IPO Year
- FGBI N/A
- OBIO N/A
- Fundamental
- Price
- FGBI $8.28
- OBIO $3.01
- Analyst Decision
- FGBI
- OBIO Strong Buy
- Analyst Count
- FGBI 0
- OBIO 5
- Target Price
- FGBI N/A
- OBIO $14.20
- AVG Volume (30 Days)
- FGBI 20.6K
- OBIO 243.1K
- Earning Date
- FGBI 07-22-2025
- OBIO 08-11-2025
- Dividend Yield
- FGBI 0.47%
- OBIO N/A
- EPS Growth
- FGBI N/A
- OBIO N/A
- EPS
- FGBI 0.13
- OBIO N/A
- Revenue
- FGBI $81,247,000.00
- OBIO $2,886,000.00
- Revenue This Year
- FGBI N/A
- OBIO $20.47
- Revenue Next Year
- FGBI $3.38
- OBIO $11.45
- P/E Ratio
- FGBI $61.50
- OBIO N/A
- Revenue Growth
- FGBI N/A
- OBIO 30.23
- 52 Week Low
- FGBI $6.56
- OBIO $2.37
- 52 Week High
- FGBI $15.25
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- FGBI 44.50
- OBIO 47.82
- Support Level
- FGBI $7.40
- OBIO $2.91
- Resistance Level
- FGBI $9.01
- OBIO $3.48
- Average True Range (ATR)
- FGBI 0.31
- OBIO 0.26
- MACD
- FGBI -0.06
- OBIO -0.01
- Stochastic Oscillator
- FGBI 55.28
- OBIO 28.78
About FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.